Last $7.57 USD
Change Today +0.02 / 0.26%
Volume 1.3M
HALO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$7.54
Previous Close
$7.55
Day High
$7.80
Day Low
$7.37
52 Week High
01/24/14 - $18.18
52 Week Low
04/19/13 - $5.52
Market Cap
942.3M
Average Volume 10 Days
4.8M
EPS TTM
$-0.73
Shares Outstanding
124.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

170 Employees
Last Reported Date: 02/28/14
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.9K
Vice President, General Counsel and Secretary
Total Annual Compensation: $317.5K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics Announces Management Changes

Halozyme Therapeutics, Inc. has appointed Sunil Joshi as vice president and global product team lead, or GPTL, for PEGPH20 and oncology; and Stephen Daly as vice president for Hylenex sales and marketing. Mr. Joshi most recently served as Head of New Product Strategy and Commercial Assessment at Onyx Pharmaceuticals where he co-led the activities to identify, value and acquire new oncology assets for Onyx. Stephen Daly will assume leadership of the current sales and marketing efforts for Hylenex in addition to continuing to lead the team involved in preparing for the potential approval and subsequent launch of Hylenex for use in the pretreatment of the insulin infusion site for people with type 1 diabetes using insulin pumps. Mr. Daly joined Halozyme in July 2013 as Executive Director, Endocrinology Marketing. Mr. Daly is replacing James Shaffer, Halozyme's Chief Commercial Officer who resigned effective March 31, 2014, to spend more time with his family on the east coast.

Halozyme Therapeutics, Inc. Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20

Halozyme Therapeutics, Inc. announced that as a result of a recommendation received from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20. The Company is halting enrollment and dosing of PEGPH20 as precautionary actions while the DMC's full evaluation of the data is ongoing.

Halozyme Therapeutics, Inc. Announces Executive Changes

Halozyme Therapeutics, Inc. announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead (GPTL), for PEGPH20 and Oncology. With over 20 years of experience in the biopharmaceutical industry, Mr. Joshi brings strong expertise in oncology drug development and commercialization. Joshi most recently served as Head of New Product Strategy and Commercial Assessment at Onyx Pharmaceuticals where he co--led the activities to identify, value and acquire new oncology assets for Onyx. In addition, Stephen Daly has been named Vice President, Hylenex(R) Sales & Marketing and will assume leadership of the current sales and marketing efforts for Hylenex in addition to continuing to lead the team involved in preparing for the potential approval and subsequent launch of Hylenex for use in the pretreatment of the insulin infusion site for people with type 1 diabetes using insulin pumps. Most recently Mr. Joshi served as Oncology Business Unit leader for the Intercontinental Region, responsible for product launches and commercialization of oncology products including Erbitux(R), Ixempra(R), and Yervoy(R) across multiple solid tumors (colorectal cancer, head and neck cancer, melanoma and breast cancer) and Sprycel(R) in chronic myelogenous leukemia, and Philadelphia positive, acute lymphoblastic leukemia. Daly joined Halozyme in July 2013 as Executive Director, Endocrinology Marketing. Prior to Halozyme, Daly worked at Amylin for six years in increasingly senior roles in endocrinology marketing for products including Byetta(R) and Symlin(R). Daly is replacing James Shaffer, Halozyme's Chief Commercial Officer who resigned effective March 31, 2014, to spend more time with his family on the east coast. Mr. Shaffer will continue working with the company as a consultant during a transition period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $7.57 USD +0.02

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HALO.
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.